Displaying 151–175 of 11050 results for

Sort By Relevance Sort By Date
1... 5 6 7 8 9 ...442

States probe Eli Lilly over insulin prices

(News)

Eli Lilly has been hit with a subpoena from the New York Attorney General’s Office over the pricing and sales of its insulin treatments.

Union says Takeda employees treated unfairly during merger

(News)

Takeda Pharma's Korean labor union said Takeda employees faced unfair changes in their jobs and roles during the Takeda Korea and Shire Korea merger.

Fujifilm drops $890M on Danish biologics campus

(News)

Fujifilm has acquired a large-scale biologics site near Copenhagen, Denmark.

Oklahoma guns for $17B settlement in J&J opioid litigation

(News)

Oklahoma’s attorney general has made a final attempt to hold Johnson & Johnson’s feet to the fire for its role in the opioid epidemic.

Pharma in review: trending stories 8/2/19

(News)

pharma manufacturing news in review

Research report: Data — the land of lost opportunity

(Whitepaper)

Without the right data management systems in place, data is nothing more than spreadsheets of wasted opportunity for improvement.

What’s behind all the M&A deals in pharma?

(Article)

As far as M&A deals go, 2019 has started off with a boom.

Mylan looks to settle EpiPen probe for $30M

(News)

Mylan has reached a tentative agreement to resolve an investigation that it underpaid the government for EpiPens.

Trump forms plan to allow imported meds from Canada

(News)

In his latest attempt to lower the costs of prescription drugs, President Trump has proposed a plan to allow imports from Canada.

FTC probing J&J over arthritis drug Remicade

(News)

The organization issued a civil investigative demand to the drugmaker to see if its biosimilar defense strategy violates federal antitrust laws.

Celgene resolves cancer drug antitrust case with Mylan

(News)

The drugmaker will pay Mylan $62 million for improperly stifling competition for its cancer drugs.

New painkiller that seemed destined for greatness may only get limited FDA nod

(News)

One of the buzziest new painkillers in trials for the last few years has been Pfizer and Ely Lilly’s tanezumab, a nerve growth factor drug.

Novartis CEO says he won't sell Sandoz unit

(News)

Novartis CEO Vas Narasimhan pledged in a published interview that the Swiss drugmaker will not sell its generics unit amid a revamp that has prompted rumors about offloading Sandoz.

Potential Novartis blockbuster misses the mark in new study

(News)

Novartis’ Entresto already has the potential to hit $3 billion in sales for its current heart failure indication, and with another indication in mind, the company hoped sales could hit $5 billion.

Pfizer to combine off-patent drug business with Mylan

(News)

Pfizer has agreed to merge its off-patent drugs business with generic drugmaker Mylan.

Merck to build new plant in N.C.

(News)

Merck Sharp and Dohme will invest some $680 million in new manufacturing space and expanded packaging space to support its HPV vaccine Gardisil.

Pharma in review: trending stories 7/26/19

(News)

pharma manufacturing news in review

Vertex names new CEO

(News)

Vertex Pharmaceuticals announced that its chief medical officer, Reshma Kewalramani, will take over as president and chief executive in April 2020.

GSK hires new chairman as it prepares for split

(News)

GlaxoSmithKline has hired a former finance chief from Novartis and AstraZeneca as its new non-executive chairman.

Humira biosim wins FDA approval

(News)

The clock is ticking on how much longer the world’s best-selling drug will be free from biosimilar competition in the U.S.

Bayer recalls two lots of mislabeled hemophilia A med

(News)

The drugmaker is voluntarily recalling two lots that were filled with factor VIII hemophilia A treatment Jivi but were labeled as containing hemophilia treatment Kogenate FS.

Sanofi makes deal for Tamiflu rights from Roche

(News)

The deal will give Sanofi exclusive OTC rights to the flu treatment in the U.S.

10 of the highest-paid CEOs in pharma

(Article)

Lucrative compensation packages for CEOs are certainly not unique to pharma. But many of the industry's top dogs got hefty raises last year, showing it's a good time to be a CEO in pharma.

FDA rejects Biohaven treatment for Lou Gehrig’s disease

(News)

Biohaven Pharmaceutical Holding Co. has reported that its new treatment for armyotrophic lateral sclerosis, or Lou Gehrig’s disease, has failed to win FDA approval.

Intec Pharma drug fails in Parkinson's trial

(News)

Intec Pharma announced its Parkinson's disease hopeful missed its primary endpoint in a phase 3 trial.

Sort By Relevance Sort By Date
1... 5 6 7 8 9 ...442